Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nevus, Pigmented | 15 | 2024 | 222 | 6.620 |
Why?
|
Skin Neoplasms | 47 | 2024 | 5821 | 6.330 |
Why?
|
Melanoma | 33 | 2024 | 5709 | 4.590 |
Why?
|
Nevus, Epithelioid and Spindle Cell | 7 | 2024 | 70 | 4.390 |
Why?
|
Melanosis | 4 | 2023 | 93 | 2.250 |
Why?
|
Dermatology | 12 | 2023 | 918 | 2.070 |
Why?
|
Pigmentation Disorders | 2 | 2022 | 105 | 1.530 |
Why?
|
Basal Cell Nevus Syndrome | 2 | 2022 | 38 | 1.490 |
Why?
|
Dermoscopy | 2 | 2024 | 66 | 1.470 |
Why?
|
Skin | 12 | 2023 | 4484 | 1.370 |
Why?
|
Hair Diseases | 2 | 2022 | 72 | 1.120 |
Why?
|
Granuloma | 3 | 2023 | 328 | 0.980 |
Why?
|
Nail Diseases | 2 | 2024 | 55 | 0.920 |
Why?
|
Epidermolysis Bullosa | 1 | 2024 | 29 | 0.920 |
Why?
|
Nevus, Blue | 1 | 2023 | 43 | 0.890 |
Why?
|
Neurocutaneous Syndromes | 2 | 2023 | 53 | 0.880 |
Why?
|
Sentinel Lymph Node Biopsy | 6 | 2023 | 732 | 0.860 |
Why?
|
Scalp Dermatoses | 1 | 2022 | 44 | 0.810 |
Why?
|
DNA, Neoplasm | 2 | 2020 | 1745 | 0.810 |
Why?
|
Callosities | 1 | 2021 | 4 | 0.800 |
Why?
|
Sunburn | 2 | 2019 | 156 | 0.770 |
Why?
|
Skin Diseases | 5 | 2024 | 1094 | 0.760 |
Why?
|
Skin Diseases, Viral | 1 | 2021 | 26 | 0.760 |
Why?
|
Nevus of Ota | 1 | 2021 | 3 | 0.760 |
Why?
|
Child | 42 | 2024 | 80153 | 0.750 |
Why?
|
Granuloma, Pyogenic | 1 | 2021 | 47 | 0.750 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2024 | 455 | 0.750 |
Why?
|
Skin Abnormalities | 1 | 2021 | 59 | 0.740 |
Why?
|
Pseudoxanthoma Elasticum | 1 | 2020 | 14 | 0.740 |
Why?
|
Penicillamine | 1 | 2020 | 60 | 0.740 |
Why?
|
Hepatolenticular Degeneration | 1 | 2020 | 72 | 0.720 |
Why?
|
Carcinoma, Basal Cell | 3 | 2020 | 560 | 0.710 |
Why?
|
Nevus | 1 | 2022 | 205 | 0.710 |
Why?
|
Cumulative Trauma Disorders | 1 | 2021 | 151 | 0.690 |
Why?
|
Fingers | 1 | 2021 | 507 | 0.620 |
Why?
|
Aluminum Compounds | 1 | 2018 | 55 | 0.610 |
Why?
|
Acne Vulgaris | 1 | 2022 | 358 | 0.570 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2022 | 4352 | 0.560 |
Why?
|
Hypersensitivity, Delayed | 1 | 2018 | 490 | 0.550 |
Why?
|
Urticaria | 1 | 2018 | 150 | 0.540 |
Why?
|
Cleft Lip | 1 | 2021 | 506 | 0.520 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2021 | 621 | 0.520 |
Why?
|
Cleft Palate | 1 | 2021 | 589 | 0.510 |
Why?
|
Drug Eruptions | 3 | 2014 | 335 | 0.500 |
Why?
|
Sweat Gland Diseases | 1 | 2015 | 12 | 0.500 |
Why?
|
Chlorides | 1 | 2018 | 665 | 0.490 |
Why?
|
Eccrine Glands | 1 | 2015 | 52 | 0.480 |
Why?
|
Child, Preschool | 20 | 2024 | 42230 | 0.470 |
Why?
|
Urinary Bladder | 5 | 2008 | 1152 | 0.460 |
Why?
|
Tumor Suppressor Proteins | 1 | 2024 | 2803 | 0.460 |
Why?
|
Dermatitis, Atopic | 4 | 2024 | 731 | 0.460 |
Why?
|
Adolescent | 27 | 2024 | 88319 | 0.450 |
Why?
|
Humans | 87 | 2024 | 761504 | 0.450 |
Why?
|
Abnormalities, Multiple | 1 | 2021 | 1423 | 0.450 |
Why?
|
Infant | 17 | 2024 | 36192 | 0.450 |
Why?
|
Leg Injuries | 1 | 2015 | 179 | 0.430 |
Why?
|
Biopsy | 7 | 2021 | 6766 | 0.430 |
Why?
|
Hamartoma | 1 | 2015 | 235 | 0.420 |
Why?
|
Giant Cells | 1 | 2013 | 188 | 0.400 |
Why?
|
Central Nervous System Neoplasms | 1 | 2021 | 916 | 0.400 |
Why?
|
Telemedicine | 4 | 2022 | 3051 | 0.400 |
Why?
|
Diagnosis, Differential | 7 | 2024 | 12974 | 0.390 |
Why?
|
Language | 1 | 2021 | 1540 | 0.390 |
Why?
|
Clobetasol | 2 | 2014 | 33 | 0.380 |
Why?
|
Anti-Inflammatory Agents | 2 | 2012 | 1809 | 0.380 |
Why?
|
Cyclin D1 | 1 | 2013 | 451 | 0.360 |
Why?
|
Scalp | 2 | 2023 | 389 | 0.350 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2014 | 549 | 0.340 |
Why?
|
Pyoderma Gangrenosum | 1 | 2010 | 84 | 0.320 |
Why?
|
Ultraviolet Rays | 1 | 2014 | 1080 | 0.320 |
Why?
|
Carcinoma, Merkel Cell | 1 | 2012 | 328 | 0.310 |
Why?
|
Pathology, Clinical | 1 | 2012 | 376 | 0.310 |
Why?
|
Exocytosis | 3 | 2008 | 320 | 0.300 |
Why?
|
Mutation | 2 | 2024 | 30052 | 0.250 |
Why?
|
Eczema | 2 | 2018 | 246 | 0.250 |
Why?
|
Vaccination | 1 | 2018 | 3384 | 0.250 |
Why?
|
Anti-Bacterial Agents | 1 | 2023 | 7407 | 0.240 |
Why?
|
Magnetic Resonance Imaging | 5 | 2024 | 36426 | 0.240 |
Why?
|
Retrospective Studies | 17 | 2024 | 80636 | 0.230 |
Why?
|
Female | 36 | 2024 | 392644 | 0.230 |
Why?
|
Hospitalization | 1 | 2024 | 10723 | 0.230 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2024 | 2057 | 0.230 |
Why?
|
Male | 32 | 2024 | 360804 | 0.220 |
Why?
|
Azetidines | 1 | 2024 | 142 | 0.220 |
Why?
|
Immunohistochemistry | 5 | 2024 | 11076 | 0.210 |
Why?
|
Adrenal Cortex Hormones | 2 | 2018 | 1880 | 0.210 |
Why?
|
Trientine | 1 | 2020 | 12 | 0.190 |
Why?
|
Pamphlets | 1 | 2020 | 71 | 0.180 |
Why?
|
Young Adult | 11 | 2024 | 59243 | 0.180 |
Why?
|
Melanins | 1 | 2022 | 290 | 0.170 |
Why?
|
Glucocorticoids | 2 | 2021 | 2161 | 0.170 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4544 | 0.170 |
Why?
|
Genomics | 2 | 2022 | 5821 | 0.170 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2021 | 147 | 0.170 |
Why?
|
Aminoquinolines | 1 | 2020 | 107 | 0.170 |
Why?
|
Lip | 1 | 2021 | 197 | 0.170 |
Why?
|
Immunologic Factors | 2 | 2022 | 1589 | 0.170 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2020 | 4026 | 0.150 |
Why?
|
Ambulatory Care Facilities | 2 | 2021 | 935 | 0.150 |
Why?
|
Hospital Costs | 1 | 2024 | 947 | 0.150 |
Why?
|
Communication Barriers | 1 | 2021 | 413 | 0.150 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2008 | 180 | 0.150 |
Why?
|
Patch Tests | 1 | 2018 | 57 | 0.150 |
Why?
|
Remote Consultation | 1 | 2020 | 237 | 0.150 |
Why?
|
Sunlight | 1 | 2019 | 337 | 0.150 |
Why?
|
Histamine Antagonists | 1 | 2018 | 92 | 0.140 |
Why?
|
Age of Onset | 1 | 2024 | 3305 | 0.140 |
Why?
|
Urination | 1 | 2008 | 203 | 0.140 |
Why?
|
Adult | 15 | 2024 | 221177 | 0.140 |
Why?
|
rab GTP-Binding Proteins | 1 | 2008 | 250 | 0.140 |
Why?
|
Comparative Genomic Hybridization | 1 | 2018 | 473 | 0.140 |
Why?
|
Antibodies, Monoclonal | 2 | 2012 | 9177 | 0.130 |
Why?
|
Positron-Emission Tomography | 1 | 2012 | 6485 | 0.130 |
Why?
|
Down Syndrome | 1 | 2024 | 901 | 0.130 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2019 | 5671 | 0.130 |
Why?
|
Acneiform Eruptions | 1 | 2014 | 4 | 0.120 |
Why?
|
Dermatitis, Phototoxic | 1 | 2014 | 17 | 0.120 |
Why?
|
Health Services Accessibility | 3 | 2022 | 5440 | 0.120 |
Why?
|
Neurons, Afferent | 1 | 2007 | 498 | 0.120 |
Why?
|
Parents | 2 | 2019 | 3563 | 0.120 |
Why?
|
Fluorouracil | 1 | 2020 | 1641 | 0.120 |
Why?
|
Biopsy, Needle | 2 | 2017 | 1626 | 0.120 |
Why?
|
Mohs Surgery | 1 | 2017 | 222 | 0.120 |
Why?
|
Receptors, Purinergic P2 | 1 | 2005 | 150 | 0.120 |
Why?
|
Hyperalgesia | 1 | 2008 | 531 | 0.110 |
Why?
|
Antifungal Agents | 2 | 2019 | 752 | 0.110 |
Why?
|
Photography | 1 | 2017 | 532 | 0.110 |
Why?
|
Urothelium | 1 | 2005 | 269 | 0.110 |
Why?
|
Interferons | 1 | 2017 | 706 | 0.110 |
Why?
|
Prognosis | 4 | 2023 | 29625 | 0.110 |
Why?
|
Physostigmine | 1 | 2002 | 50 | 0.110 |
Why?
|
Estrous Cycle | 1 | 2002 | 65 | 0.100 |
Why?
|
Leg | 1 | 2018 | 1088 | 0.100 |
Why?
|
Boston | 2 | 2023 | 9326 | 0.100 |
Why?
|
Administration, Topical | 2 | 2014 | 704 | 0.100 |
Why?
|
Patient Care Planning | 1 | 2018 | 908 | 0.100 |
Why?
|
Laminin | 1 | 2014 | 408 | 0.100 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2013 | 197 | 0.100 |
Why?
|
Pemphigoid, Bullous | 1 | 2014 | 112 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 2510 | 0.100 |
Why?
|
Infant, Newborn | 4 | 2024 | 26198 | 0.100 |
Why?
|
Mycophenolic Acid | 1 | 2014 | 348 | 0.100 |
Why?
|
Lower Extremity | 2 | 2017 | 1202 | 0.100 |
Why?
|
Neoplasm Invasiveness | 2 | 2017 | 3595 | 0.100 |
Why?
|
Documentation | 1 | 2018 | 897 | 0.100 |
Why?
|
Comorbidity | 2 | 2024 | 10508 | 0.090 |
Why?
|
Cholinesterase Inhibitors | 1 | 2002 | 242 | 0.090 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 3514 | 0.090 |
Why?
|
Rheumatoid Nodule | 1 | 2010 | 15 | 0.090 |
Why?
|
Survival Rate | 3 | 2024 | 12725 | 0.090 |
Why?
|
Necrobiosis Lipoidica | 1 | 2010 | 14 | 0.090 |
Why?
|
Xanthomatosis | 1 | 2010 | 32 | 0.090 |
Why?
|
Measles | 1 | 2012 | 183 | 0.090 |
Why?
|
Caregivers | 1 | 2022 | 2237 | 0.090 |
Why?
|
Alopecia | 2 | 2018 | 412 | 0.090 |
Why?
|
Risk Factors | 8 | 2023 | 74206 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2020 | 2759 | 0.090 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2012 | 585 | 0.080 |
Why?
|
Age Factors | 4 | 2020 | 18395 | 0.080 |
Why?
|
Pituitary-Adrenal System | 1 | 2002 | 552 | 0.080 |
Why?
|
Cohort Studies | 5 | 2024 | 41487 | 0.080 |
Why?
|
Cell Membrane | 2 | 2007 | 3688 | 0.080 |
Why?
|
Patient Compliance | 1 | 2019 | 2690 | 0.080 |
Why?
|
Monitoring, Physiologic | 1 | 2017 | 1779 | 0.080 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2014 | 664 | 0.080 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20570 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1052 | 0.080 |
Why?
|
Adenosine Triphosphate | 1 | 2005 | 1989 | 0.080 |
Why?
|
Patient Care Team | 2 | 2019 | 2521 | 0.080 |
Why?
|
Survivors | 1 | 2019 | 2371 | 0.080 |
Why?
|
Curriculum | 1 | 2022 | 3743 | 0.080 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2002 | 701 | 0.080 |
Why?
|
Referral and Consultation | 3 | 2021 | 3600 | 0.080 |
Why?
|
Reference Standards | 1 | 2012 | 1003 | 0.080 |
Why?
|
Lichen Planus | 1 | 2009 | 70 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2019 | 9280 | 0.080 |
Why?
|
Sjogren's Syndrome | 1 | 2010 | 237 | 0.080 |
Why?
|
Lung Neoplasms | 1 | 2013 | 13380 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2013 | 1834 | 0.070 |
Why?
|
Dermatitis | 1 | 2010 | 202 | 0.070 |
Why?
|
Health Behavior | 1 | 2019 | 2643 | 0.070 |
Why?
|
Postoperative Complications | 1 | 2010 | 15631 | 0.070 |
Why?
|
Interleukins | 1 | 2012 | 782 | 0.070 |
Why?
|
United States | 7 | 2024 | 72334 | 0.070 |
Why?
|
Physicians | 2 | 2023 | 4591 | 0.070 |
Why?
|
Massachusetts | 1 | 2020 | 8830 | 0.070 |
Why?
|
Eosinophils | 1 | 2012 | 950 | 0.070 |
Why?
|
Paraproteinemias | 1 | 2010 | 248 | 0.070 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1085 | 0.070 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8529 | 0.070 |
Why?
|
Lipomatosis | 1 | 2007 | 112 | 0.070 |
Why?
|
Biological Specimen Banks | 1 | 2012 | 783 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1405 | 0.070 |
Why?
|
Intestine, Small | 1 | 2012 | 1206 | 0.070 |
Why?
|
Appointments and Schedules | 2 | 2020 | 443 | 0.070 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4111 | 0.060 |
Why?
|
Hair | 1 | 2009 | 498 | 0.060 |
Why?
|
Immunosuppressive Agents | 2 | 2019 | 4174 | 0.060 |
Why?
|
Autoantibodies | 1 | 2014 | 2116 | 0.060 |
Why?
|
Neoplasm Staging | 2 | 2017 | 11121 | 0.060 |
Why?
|
Genetic Testing | 1 | 2018 | 3537 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2012 | 1265 | 0.060 |
Why?
|
Bone Marrow Transplantation | 1 | 2012 | 2693 | 0.060 |
Why?
|
Incidence | 2 | 2020 | 21353 | 0.060 |
Why?
|
Sarcoidosis | 1 | 2010 | 521 | 0.060 |
Why?
|
Cross-Sectional Studies | 6 | 2022 | 26125 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2018 | 4016 | 0.050 |
Why?
|
Immunotherapy | 1 | 2019 | 4652 | 0.050 |
Why?
|
Cell Proliferation | 1 | 2019 | 10445 | 0.050 |
Why?
|
Methotrexate | 1 | 2010 | 1719 | 0.050 |
Why?
|
Early Detection of Cancer | 3 | 2022 | 3201 | 0.050 |
Why?
|
Risk Assessment | 3 | 2023 | 23995 | 0.050 |
Why?
|
Staphylococcus aureus | 1 | 2010 | 1458 | 0.050 |
Why?
|
Hypertrichosis | 1 | 2021 | 31 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2019 | 39106 | 0.050 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2024 | 287 | 0.050 |
Why?
|
Skin Care | 1 | 2021 | 57 | 0.050 |
Why?
|
Hair Removal | 1 | 2021 | 40 | 0.050 |
Why?
|
Middle Aged | 8 | 2024 | 220895 | 0.050 |
Why?
|
Antineoplastic Agents | 3 | 2019 | 13639 | 0.050 |
Why?
|
Purines | 1 | 2024 | 607 | 0.050 |
Why?
|
Electronics | 1 | 2021 | 318 | 0.040 |
Why?
|
Antirheumatic Agents | 1 | 2010 | 1372 | 0.040 |
Why?
|
Rabbits | 2 | 2007 | 4772 | 0.040 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 3029 | 0.040 |
Why?
|
Stem Cells | 1 | 2012 | 3522 | 0.040 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2007 | 1897 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2122 | 0.040 |
Why?
|
International Classification of Diseases | 1 | 2024 | 909 | 0.040 |
Why?
|
Cytoplasmic Vesicles | 1 | 2008 | 73 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2024 | 64680 | 0.040 |
Why?
|
Neoplasm Transplantation | 1 | 2022 | 2016 | 0.040 |
Why?
|
Pruritus | 1 | 2021 | 380 | 0.040 |
Why?
|
Reflex, Abnormal | 1 | 2008 | 83 | 0.040 |
Why?
|
Primary Health Care | 3 | 2020 | 4686 | 0.040 |
Why?
|
Emollients | 1 | 2018 | 42 | 0.040 |
Why?
|
Cystitis | 1 | 2008 | 95 | 0.040 |
Why?
|
Baths | 1 | 2018 | 53 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2013 | 5305 | 0.040 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2010 | 2155 | 0.040 |
Why?
|
Cell Shape | 1 | 2008 | 371 | 0.040 |
Why?
|
Crohn Disease | 1 | 2010 | 2279 | 0.040 |
Why?
|
Iatrogenic Disease | 1 | 2020 | 539 | 0.040 |
Why?
|
Vitiligo | 1 | 2018 | 97 | 0.030 |
Why?
|
Neutrophils | 1 | 2010 | 3767 | 0.030 |
Why?
|
Transforming Growth Factor alpha | 1 | 2007 | 135 | 0.030 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2013 | 8547 | 0.030 |
Why?
|
Cycloheximide | 1 | 2007 | 343 | 0.030 |
Why?
|
Mutant Proteins | 1 | 2008 | 491 | 0.030 |
Why?
|
Quality of Life | 1 | 2018 | 13367 | 0.030 |
Why?
|
Nurse Practitioners | 1 | 2019 | 271 | 0.030 |
Why?
|
Phenotype | 1 | 2014 | 16591 | 0.030 |
Why?
|
Disease Management | 2 | 2018 | 2508 | 0.030 |
Why?
|
Patients | 1 | 2023 | 907 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4021 | 0.030 |
Why?
|
Capital Financing | 1 | 2016 | 58 | 0.030 |
Why?
|
Electric Capacitance | 1 | 2005 | 14 | 0.030 |
Why?
|
Receptors, Purinergic P2X2 | 1 | 2005 | 8 | 0.030 |
Why?
|
Receptors, Purinergic P2X3 | 1 | 2005 | 9 | 0.030 |
Why?
|
Purinergic P2 Receptor Agonists | 1 | 2005 | 13 | 0.030 |
Why?
|
Mice, Knockout | 3 | 2012 | 14414 | 0.030 |
Why?
|
Office Visits | 1 | 2020 | 595 | 0.030 |
Why?
|
Transduction, Genetic | 1 | 2008 | 903 | 0.030 |
Why?
|
Physical Examination | 1 | 2021 | 1255 | 0.030 |
Why?
|
Pyridoxal Phosphate | 1 | 2005 | 125 | 0.030 |
Why?
|
Waiting Lists | 1 | 2020 | 765 | 0.030 |
Why?
|
Brain | 1 | 2022 | 27112 | 0.030 |
Why?
|
Receptor, erbB-2 | 2 | 2014 | 2557 | 0.030 |
Why?
|
Benzoyl Peroxide | 1 | 2014 | 22 | 0.030 |
Why?
|
Cost of Illness | 1 | 2024 | 1936 | 0.030 |
Why?
|
Sulfonamides | 1 | 2024 | 1978 | 0.030 |
Why?
|
Research | 1 | 2023 | 1982 | 0.030 |
Why?
|
Clindamycin | 1 | 2014 | 139 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 2007 | 701 | 0.030 |
Why?
|
Pyrazoles | 1 | 2024 | 2009 | 0.030 |
Why?
|
Population Surveillance | 1 | 2024 | 2598 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2012 | 20098 | 0.030 |
Why?
|
Rats, Sprague-Dawley | 2 | 2007 | 8181 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2014 | 58976 | 0.030 |
Why?
|
Needs Assessment | 1 | 2019 | 1139 | 0.030 |
Why?
|
Time Factors | 2 | 2018 | 39967 | 0.030 |
Why?
|
Aftercare | 1 | 2019 | 914 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2008 | 642 | 0.030 |
Why?
|
Mucous Membrane | 1 | 2007 | 659 | 0.030 |
Why?
|
Minocycline | 1 | 2014 | 169 | 0.030 |
Why?
|
Mice | 5 | 2022 | 81525 | 0.030 |
Why?
|
Outpatients | 1 | 2021 | 1597 | 0.030 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2005 | 484 | 0.030 |
Why?
|
Apyrase | 1 | 2005 | 373 | 0.030 |
Why?
|
Arginine Vasopressin | 1 | 2002 | 125 | 0.030 |
Why?
|
Epithelium | 1 | 2007 | 1603 | 0.030 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2022 | 2425 | 0.030 |
Why?
|
Sampling Studies | 1 | 2014 | 615 | 0.030 |
Why?
|
Sensory Receptor Cells | 1 | 2007 | 513 | 0.030 |
Why?
|
Oximes | 1 | 2014 | 303 | 0.030 |
Why?
|
Tyrosine | 1 | 2007 | 1440 | 0.030 |
Why?
|
Mice, Inbred C57BL | 3 | 2012 | 22169 | 0.030 |
Why?
|
Motivation | 1 | 2022 | 2006 | 0.030 |
Why?
|
Radiotherapy | 1 | 2019 | 1499 | 0.030 |
Why?
|
Pyrimidines | 1 | 2024 | 3028 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2007 | 1246 | 0.020 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2013 | 293 | 0.020 |
Why?
|
Corticosterone | 1 | 2002 | 305 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 1403 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2014 | 713 | 0.020 |
Why?
|
Cell Line, Transformed | 1 | 2013 | 867 | 0.020 |
Why?
|
Mycoses | 1 | 2014 | 386 | 0.020 |
Why?
|
Pyrimidinones | 1 | 2014 | 385 | 0.020 |
Why?
|
Receptors, Interleukin | 1 | 2012 | 243 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2010 | 5840 | 0.020 |
Why?
|
Aged | 4 | 2024 | 169289 | 0.020 |
Why?
|
Endocytosis | 1 | 2005 | 957 | 0.020 |
Why?
|
Interleukin-23 | 1 | 2012 | 201 | 0.020 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2013 | 259 | 0.020 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2002 | 618 | 0.020 |
Why?
|
Wound Healing | 1 | 2021 | 2805 | 0.020 |
Why?
|
Animals | 6 | 2022 | 168459 | 0.020 |
Why?
|
Public Health | 1 | 2023 | 2669 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2002 | 499 | 0.020 |
Why?
|
Psoriasis | 1 | 2018 | 950 | 0.020 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2007 | 1651 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4511 | 0.020 |
Why?
|
Autoantigens | 1 | 2014 | 891 | 0.020 |
Why?
|
Melanocytes | 1 | 2013 | 509 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2014 | 856 | 0.020 |
Why?
|
Signal Transduction | 3 | 2007 | 23445 | 0.020 |
Why?
|
Patient Education as Topic | 1 | 2019 | 2319 | 0.020 |
Why?
|
Glycoproteins | 1 | 2007 | 2203 | 0.020 |
Why?
|
Rats | 2 | 2007 | 23742 | 0.020 |
Why?
|
Pyridones | 1 | 2014 | 809 | 0.020 |
Why?
|
Causality | 1 | 2014 | 1242 | 0.020 |
Why?
|
Gene Amplification | 1 | 2013 | 1089 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2020 | 17904 | 0.020 |
Why?
|
Pain Measurement | 1 | 2008 | 3550 | 0.020 |
Why?
|
Imidazoles | 1 | 2014 | 1180 | 0.020 |
Why?
|
Drug Combinations | 1 | 2014 | 2048 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2014 | 21012 | 0.020 |
Why?
|
Health Care Reform | 1 | 2016 | 1247 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 3205 | 0.020 |
Why?
|
Phosphorylation | 1 | 2007 | 8320 | 0.020 |
Why?
|
Cystic Fibrosis | 1 | 2014 | 1285 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2007 | 3673 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2012 | 6216 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2016 | 5492 | 0.010 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2013 | 2825 | 0.010 |
Why?
|
Pediatrics | 1 | 2018 | 3589 | 0.010 |
Why?
|
Quality Improvement | 1 | 2018 | 3801 | 0.010 |
Why?
|
Health Personnel | 1 | 2016 | 3335 | 0.010 |
Why?
|
Molecular Targeted Therapy | 1 | 2014 | 2811 | 0.010 |
Why?
|
Calcium | 1 | 2005 | 5722 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2012 | 5869 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 22176 | 0.010 |
Why?
|
Neoplasms | 1 | 2010 | 22170 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8654 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2018 | 15842 | 0.010 |
Why?
|
Sex Factors | 1 | 2002 | 10552 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5336 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13506 | 0.010 |
Why?
|
Apoptosis | 1 | 2013 | 9486 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2013 | 16981 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18252 | 0.010 |
Why?
|
HIV Infections | 1 | 2007 | 17351 | 0.000 |
Why?
|